Pharmacyclics has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see the disclaimer for this website.
Pharmacyclics Inc. (Nasdaq: PCYC) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs. Currently, we have three candidates in clinical development and several molecules in preclinical development.
- PCI-32765, first-in-human oral therapy that is a selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor being investigated in B-cell hematologic malignancies.
- PCI-27483, a subcutaneously administered Factor VIIa inhibitor targeting tissue factor expressing tumors in oncology (being investigated in pancreatic cancer).
- PCI-24781, abexinostat hydrochloride, an oral Histone Deacetylase (HDAC) inhibitor being investigated in oncology applications, such as lymphomas and solid tumor malignancies.
- BTK Inhibitor compounds for autoimmune diseases in preclinical development.
- Isoform selective HDAC8 inhibitors in preclinical development.
Recent Releases
Dec 19, 2011
Pharmacyclics Inc. Receives Issue Notice of Significant Bruton's Tyrosine Kinase (BTK) Patent
Events
 |
Jan 11, 2012 | 30th Annual J.P. Morgan Healthcare Conference |
|
Dec 14, 2011 | Pharmacyclics ASH Annual Meeting Conference Call |
